14:00–14:25

Abstract LBA3

CALGB/SWOG 80405: Phase III trial of   irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin   (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with   KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or   rectum (MCRC).

CALGB/SWOG 80405：FOLFIRI/mFOLFOX6联合贝伐珠单抗或西妥昔单抗用于KRAS野生型转移性结直肠腺癌初治患者的III期研究。

陈  功(Gong   Chen)

Abstract 3503^

Maintenance strategy with   fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment,   following a standard combination of FP, oxaliplatin (Ox), and Bev as   first-line treatment for patients with metastatic colorectal cancer (mCRC): A   phase III non-inferiority trial (AIO KRK 0207).

转移性结直肠癌接受氟化嘧啶（FP）/奥沙利铂/贝伐珠单抗（Bev）联合的标准一线治疗后，FP加Bev或Bev单药维持治疗或不治疗：一项III期非劣效性研究（AIO KRK 0207）。

Abstract 3504

Final results and subgroup   analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine   + bevacizumab versus observation after induction treatment with chemotherapy   + bevacizumab in metastatic colorectal cancer (mCRC).

III期研究CAIRO3的最终结果和亚组分析：转移性结直肠癌接受化疗+贝伐珠单抗诱导化疗后，卡培他滨+贝伐珠单抗维持治疗对比单纯观察。

14:25–14:35

专家评述

Discussion Topic: Ultimate words on the role of maintenance therapy   for metastatic CRC

讨论主题：维持治疗在转移性结直肠癌中的价值——尘埃落定

刘云鹏(Yun-Peng   Liu)

14:35–14:40

讨论(Q &   A)

李  进(Jin Li)

徐瑞华(Rui-Hua Xu)

刘云鹏(Yun-Peng Liu)